Drug Development

The partnership aims to provide end-to-end development and manufacturing for biopharmaceutical drug substance and drug product.

With the acquisition, Biogen gains felzartamab, HI-Bio's lead investigational mAb candidate being developed for the treatment of a range of immune-mediated diseases.

Webinar Date/Time: Mon, Jun 24, 2024 11:00 AM EDT

The new facility will be the company’s first to offer full manufacturing processing for antibody drug conjugates.

Bari Kowal, senior vice-president, head Development Operations & Portfolio Management, Regeneron, discussed the utility of AI and how it can benefit R&D work.

Ken Keller, president and CEO, Daiichi Sankyo, discusses the foundation of partnership and takes a look at the future of biotech partnerships at the US Pharma and Biotech Summit.

Webinar Date/Time: Wednesday, May 29th 11am EDT | 4pm GMT | 5pm CEST

Webinar Date/Time: Wed, Jun 12, 2024 11:00 AM EDT

Regeneron's Sven Moller-Tank, PhD, director of Viral Delivery Technologies, Regeneron Genetic Medicines, discusses the company's work in using bispecific antibodies for redirecting AAV target specificity.

At CPHI NA, Rachel Harris, AstraZeneca, spoke on her work at BioPhorum to enable industry consensus and action for sustainability with drug delivery devices.

The company’s presentation at ASGCT includes preliminary data results for a child who received the gene therapy.

A greater understanding of molecular and cellular biology and technological advancements are revolutionizing the field of biologics.

The company is presenting preclinical data at the American Society of Gene & Cell Therapy annual meeting that supports the potential of the company’s CAP-002 gene therapy for correcting neurological phenotypes associated with genetic epilepsy due to syntaxin-binding protein 1 (STXBP1) mutations.

Novel delivery technologies enhance brain penetration to target neurodegenerative diseases and glioblastomas.

The two companies will combine their cell therapy platforms to develop convertibleCAR programs targeting solid tumors.

The use of appropriate taste-masking and appearance technologies can facilitate patient compliance.

A comparison between polysorbates and HPβCD determines the better stabilizer for biologics formulation.

In this exclusive Drug Digest video interview, Chris Spivey, Director, Industry Relations and Strategic Partnerships, talks with industry experts about various aspects of drug product stability testing.

In the new draft guidance, FDA provides recommendations on cell safety testing of human-sourced allogeneic cells for sponsor companies.

Webinar Date/Time: Tue, Jun 11, 2024 10:00 AM EDT

CordenPharma’s partnership with GENEPEP expedites lead development and validation in project phases, and its LNP β-sitosterol supports sustainable emission reduction targets.

The LNP success in mRNA vaccines leads to their establishment as a standard in mRNA delivery.

In this exclusive Drug Digest video interview, Felicity Thomas, Europe/senior editor, Pharmaceutical Technology Group, interviews Dr. Krizia M. Karry, Global Head of Technical Marketing for BASF Pharma Solutions, on the topic of hot melt extrusion.

Charles River has entered into separate agreements with Axovia Therapeutics and Ship of Theseus to offer plasmid DNA manufacturing services for a gene therapy and a lead candidate program, respectively.

Webinar Date/Time: Fri, Apr 26, 2024 11:00 AM EDT

Webinar Date/Time: Wed, May 15, 2024 2:00 PM EDT

Genmab's acquisition of ProfoundBio will boost its clinical and preclinical pipeline of ADCs for targeted cancer treatment.

Advanced oral dosage forms allow for modulation of controlled- and sustained-release profiles.

Experts believe it is likely cancer cells are more common in the body than previously thought, but typically caught early and removed in the body’s cancer-immune cycle. When the system is in good working order (and protecting us), dead cancer cells release neoantigens.

FDA granted fast track designation to nipocalimab, which J&J is developing for helping alloimmunized pregnant adults treat FNAIT, a rare disease that poses risk to the fetus or newborn.